Source: Business Wire

Press Release: Gene Signal : Global Corneal Graft Rejection Pipeline Review, H1 2016 - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Corneal Graft Rejection - Pipeline Review, H1 2016" report to their offering. This report provides comprehensive information on the therapeutic development for Corneal Graft Rejection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
100-250
Eric Viaud's photo - Co-Founder & CEO of Gene Signal

Co-Founder & CEO

Eric Viaud

CEO Approval Rating

81/100

Read more